| The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5 KMA Rouschop, T van den Beucken, L Dubois, H Niessen, J Bussink, ... The Journal of clinical investigation 120 (1), 127-141, 2010 | 976 | 2010 |
| Tracking tumor biology with radiomics: a systematic review utilizing a radiomics quality score S Sanduleanu, HC Woodruff, EEC De Jong, JE Van Timmeren, ... Radiotherapy and Oncology 127 (3), 349-360, 2018 | 265 | 2018 |
| PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS KM Rouschop, LJ Dubois, TG Keulers, T van den Beucken, P Lambin, ... Proceedings of the National Academy of Sciences 110 (12), 4622-4627, 2013 | 260 | 2013 |
| Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET HJWL Aerts, L Dubois, L Perk, P Vermaelen, GAMS van Dongen, ... Journal of Nuclear Medicine 50 (1), 123-131, 2009 | 260 | 2009 |
| Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting? VS Iglesias, L Giuranno, LJ Dubois, J Theys, M Vooijs Frontiers in oncology 8, 267, 2018 | 238 | 2018 |
| How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models MW van Gisbergen, AM Voets, MHW Starmans, IFM de Coo, R Yadak, ... Mutation Research/Reviews in Mutation Research 764, 16-30, 2015 | 234 | 2015 |
| Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation L Dubois, S Peeters, NG Lieuwes, N Geusens, A Thiry, S Wigfield, F Carta, ... Radiotherapy and Oncology 99 (3), 424-431, 2011 | 217 | 2011 |
| Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies P Ebbesen, EO Pettersen, TA Gorr, G Jobst, K Williams, J Kieninger, ... Journal of enzyme inhibition and medicinal chemistry 24 (sup1), 1-39, 2009 | 213 | 2009 |
| Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model L Dubois, NG Lieuwes, A Maresca, A Thiry, CT Supuran, A Scozzafava, ... Radiotherapy and Oncology 92 (3), 423-428, 2009 | 212 | 2009 |
| A comparative study of the hypoxia PET tracers [18F] HX4,[18F] FAZA, and [18F] FMISO in a preclinical tumor model SGJA Peeters, CML Zegers, NG Lieuwes, W van Elmpt, J Eriksson, ... International Journal of Radiation Oncology* Biology* Physics 91 (2), 351-359, 2015 | 207 | 2015 |
| Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo J Theys, O Pennington, L Dubois, G Anlezark, T Vaughan, A Mengesha, ... British journal of cancer 95 (9), 1212-1219, 2006 | 187 | 2006 |
| Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis SJA van Kuijk, A Yaromina, R Houben, R Niemans, P Lambin, LJ Dubois Frontiers in oncology 6, 69, 2016 | 183 | 2016 |
| Decision support systems for personalized and participative radiation oncology P Lambin, J Zindler, BGL Vanneste, L Van De Voorde, D Eekers, ... Advanced drug delivery reviews 109, 131-153, 2017 | 175 | 2017 |
| Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors L Dubois, K Douma, CT Supuran, RK Chiu, MAMJ van Zandvoort, ... Radiotherapy and oncology 83 (3), 367-373, 2007 | 174 | 2007 |
| Preclinical evaluation and validation of [18F] HX4, a promising hypoxia marker for PET imaging LJ Dubois, NG Lieuwes, MHM Janssen, WJM Peeters, AD Windhorst, ... Proceedings of the National Academy of Sciences 108 (35), 14620-14625, 2011 | 170 | 2011 |
| Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells KM Panth, RTH Leijenaar, S Carvalho, NG Lieuwes, A Yaromina, ... Radiotherapy and Oncology 116 (3), 462-466, 2015 | 158 | 2015 |
| Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials L Spiegelberg, R Houben, R Niemans, D de Ruysscher, A Yaromina, ... Clinical and translational radiation oncology 15, 62-69, 2019 | 142 | 2019 |
| Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium EO Pettersen, P Ebbesen, RG Gieling, KJ Williams, L Dubois, P Lambin, ... Journal of enzyme inhibition and medicinal chemistry 30 (5), 689-721, 2015 | 139 | 2015 |
| Evaluation of hypoxia in an experimental rat tumour model by [18F] fluoromisonidazole PET and immunohistochemistry L Dubois, W Landuyt, K Haustermans, P Dupont, G Bormans, ... British journal of cancer 91 (11), 1947-1954, 2004 | 139 | 2004 |
| Angelo Mosso and muscular fatigue: 116 years after the first Congress of Physiologists: IUPS commemoration C Di Giulio, F Daniele, CM Tipton Advances in physiology education, 2006 | 138 | 2006 |
Philippe LambinProfessor of Precision Medicine, Maastricht University & Scientist ULBVerified email at maastrichtuniversity.nl
